Profil
Gidi Benyamini is currently the Chief Operating Officer at Notal Vision Ltd.
He previously worked as the Vice President-Engineering & Manufacturing at LaserComm Ltd.
Aktive Positionen von Gidi Benyamini
| Unternehmen | Position | Beginn |
|---|---|---|
Notal Vision Ltd.
 Notal Vision Ltd. Medical/Nursing ServicesHealth Services Notal Vision Ltd. develops and manufactures computerized ophthalmic diagnostic devices. It develops age-related macular degeneration (AMD) monitor for patients at risk of vision loss from the devastating effects of wet AMD. The firm provides Preferential Hyperacuity Perimetry, a technology with clinical data for monitoring patients with AMD to eye care professionals. Its products are used for the detection and characterization of central and paracentral metamorphopsia in patients as an aid in monitoring progression of disease factors causing metamorphopsia, such as choroidal neovascularization. The company was founded in 2000 by Barak Azmon and Yair Alster and is headquartered in Tel Aviv, Israel. | Geschäftsführer | 04.03.2013 |
Ehemalige bekannte Positionen von Gidi Benyamini
| Unternehmen | Position | Ende |
|---|---|---|
| LaserComm Ltd. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Notal Vision Ltd.
Notal Vision Ltd. Medical/Nursing ServicesHealth Services Notal Vision Ltd. develops and manufactures computerized ophthalmic diagnostic devices. It develops age-related macular degeneration (AMD) monitor for patients at risk of vision loss from the devastating effects of wet AMD. The firm provides Preferential Hyperacuity Perimetry, a technology with clinical data for monitoring patients with AMD to eye care professionals. Its products are used for the detection and characterization of central and paracentral metamorphopsia in patients as an aid in monitoring progression of disease factors causing metamorphopsia, such as choroidal neovascularization. The company was founded in 2000 by Barak Azmon and Yair Alster and is headquartered in Tel Aviv, Israel. | Health Services |
| LaserComm Ltd. |
